908 Devices Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
908 Devices heeft een totaal eigen vermogen van $126.8M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $197.5M en $70.8M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$101.53m |
| Aandelen | US$126.77m |
| Totaal verplichtingen | US$70.77m |
| Totaal activa | US$197.54m |
Recente financiële gezondheidsupdates
Recent updates
MASS: Higher 2026 Revenue Outlook Will Support A Stronger Share Price
Analysts have raised the 908 Devices fair value estimate from $11 to $13, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E that shift their overall price target framework. What’s in the News for 908 Devices 908 Devices updated full year 2026 earnings guidance, setting a revenue range of $68.0 million to $70.0 million and lifting the lower end from $67.0 million.
MASS: Raised 2026 Outlook And Index Removals Will Shape Future P/E
Analysts have raised their fair value estimate for 908 Devices from $10 to $12, citing updates to key assumptions, including the discount rate, revenue growth outlook, profit margin profile, and future P/E expectations. What’s in the News for 908 Devices 908 Devices updated its full year 2026 revenue guidance to a range of $68.0 million to $70.0 million, compared with the previous range of $67.0 million to $70.0 million.908 Devices: Mission Critical Devices Drive Growth
Summary 908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M. Valuation remains reasonable at 5.5x forward P/S, supported by a $101.5M cash position, no debt, and narrowing EBITDA losses. Read the full article on Seeking Alpha
MASS: Index Removals Will Set Up A Future Repricing Opportunity
Analysts have updated their fair value estimate for 908 Devices from $12.00 to $14.00, reflecting revised assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for 908 Devices 908 Devices was dropped from the Russell 2500 Growth Benchmark, according to index classification data.MASS: Raised 2026 Revenue Outlook Will Support A Higher Stock Price
Analysts have lifted their price target on 908 Devices stock from $10.00 to $11.00, citing updated assumptions around fair value, revenue growth, discount rate and future P/E that they consider better aligned with the company's current outlook. What’s in the News for 908 Devices 908 Devices raised its full year 2026 revenue guidance, according to a key developments summary.MASS: Raised 2026 Revenue Outlook Will Support Higher Future P/E Multiple
Analysts have modestly adjusted their price targets on 908 Devices, reflecting updated assumptions for a fair value of $10.00, a slightly higher discount rate, marginally stronger projected revenue growth, a softer profit margin outlook, and a higher future P/E of about 70x. What's in the News 908 Devices raised its full year 2026 revenue guidance to a range of $67.0 million to $70.0 million.MASS: Raised 2026 Revenue Guidance Will Support Higher Earnings Multiple
Analysts have reset their price target on 908 Devices to $10.00 from $8.00, citing updated assumptions around revenue growth, profitability, and future P/E that feed into a higher fair value estimate and a modestly higher discount rate. What's in the News 908 Devices raised full year 2026 revenue guidance to a range of $67.0 million to $70.0 million, compared with 2025 revenue, with the range described as representing 19% to 25% growth (Corporate Guidance: Raised).908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
Those holding 908 Devices Inc. ( NASDAQ:MASS ) shares would be relieved that the share price has rebounded 29% in the...Some 908 Devices Inc. (NASDAQ:MASS) Shareholders Look For Exit As Shares Take 26% Pounding
908 Devices Inc. ( NASDAQ:MASS ) shareholders won't be pleased to see that the share price has had a very rough month...908 Devices Inc.'s (NASDAQ:MASS) Share Price Not Quite Adding Up
When close to half the companies in the Electronic industry in the United States have price-to-sales ratios (or "P/S...908 Devices Inc. (NASDAQ:MASS) Analysts Are Pretty Bullish On The Stock After Recent Results
NasdaqGM:MASS 1 Year Share Price vs Fair Value Explore 908 Devices's Fair Values from the Community and select yours...US Federal And International Funding Will Expand Global Analysis Markets
The notable increase in 908 Devices’ price target reflects improved outlook due to higher expected revenue growth and an expanded forward P/E, raising the consensus fair value from $6.50 to $9.00. What's in the News 908 Devices raised its 2025 revenue guidance to $54–56 million (13–17% growth), up from prior guidance of $53–55 million.908 Devices Inc.'s (NASDAQ:MASS) Shares Climb 26% But Its Business Is Yet to Catch Up
Despite an already strong run, 908 Devices Inc. ( NASDAQ:MASS ) shares have been powering on, with a gain of 26% in the...
The New Handheld Mass Spectrometer Launch Will Expand Market Reach
Divesting the desktop bioprocessing portfolio boosts cash reserves, streamlines operations, and is expected to enhance margins and cash flow in future years.908 Devices Makes Key Divestiture (Rating Upgrade)
Summary 908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year. Read the full article on Seeking Alpha908 Devices Inc.'s (NASDAQ:MASS) 55% Jump Shows Its Popularity With Investors
The 908 Devices Inc. ( NASDAQ:MASS ) share price has done very well over the last month, posting an excellent gain of...Earnings Update: 908 Devices Inc. (NASDAQ:MASS) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on 908 Devices Inc. ( NASDAQ:MASS ), given that the company fell short...908 Devices: Key Investor Now Selling
Summary ARK Invest's recent sales of 908 Devices shares have helped to send the stock to multi-year lows. 908 Devices is seeing decent revenue growth, but large losses and limited financial flexibility raise concerns about future capital needs. The stock's low valuation compared to peers is a positive, but ongoing sales by ARK Invest could exert further downward pressure. Read the full article on Seeking AlphaWhy We're Not Concerned Yet About 908 Devices Inc.'s (NASDAQ:MASS) 29% Share Price Plunge
To the annoyance of some shareholders, 908 Devices Inc. ( NASDAQ:MASS ) shares are down a considerable 29% in the last...We Think 908 Devices (NASDAQ:MASS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Investors Appear Satisfied With 908 Devices Inc.'s (NASDAQ:MASS) Prospects
When you see that almost half of the companies in the Electronic industry in the United States have price-to-sales...Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $132.0M ) MASS } overtreffen de korte termijn passiva ( $49.4M ).
Langlopende schulden: De kortetermijnactiva MASS ( $132.0M ) overtreffen de langetermijnschulden ( $21.4M ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: MASS is schuldenvrij.
Schuld verminderen: MASS heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 11.8% was.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: Terwijl het verlieslatende MASS voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.
Voorspelling contante baan: MASS is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, zelfs bij een positieve vrije kasstroom die met 13.5 % per jaar krimpt.
Ontdek gezonde bedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/10 01:06 |
| Aandelenkoers aan het einde van de dag | 2026/09/10 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
908 Devices Inc. wordt gevolgd door 6 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Austin Moeller | Canaccord Genuity |
| Puneet Souda | Leerink Partners LLC |
| Max Masucci | Roth Capital Partners |